fda warning letter compounding semaglutide october 2025 Navigating Compounded Semaglutide: What Health Care Providers Need to Know Compounding of GLP-1 Drugs |

Key Takeaway: Topical application alone faces bioavailability limitations

In the digestive system, it slows gastric emptying the rate at which food leaves the stomach prolonging feelings of fullness and reducing the postprandial blood sugar spikes that drive hunger and cravings

It has anti-ulcer and anti-inflammatory effects (Chang CH, 2011)

Dose reduction for side effects If a dose increase triggers side effects that do not improve after two to three weeks, stepping back down to the previous dose is the standard approach

As of July 31, 2025, the FDA reported 605 adverse events linked to compounded semaglutide and 545 for compounded tirzepatide